Israel Englander Taysha Gene Therapies, Inc. Transaction History

Millennium Management LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.04 - $4.17 $5.7 Million - $11.7 Million	-2,794,593 Reduced 89.13%	340,724 $763,000
Q1 2024 May 15, 2024	SELL	$1.43 - $3.25 $350,657 - $796,948	-245,215 Reduced 7.25%	3,135,317 $9 Million
Q4 2023 Feb 14, 2024	BUY	$1.33 - $2.88 $3.68 Million - $7.96 Million	2,765,594 Added 449.74%	3,380,532 $5.98 Million
Q2 2023 Aug 14, 2023	BUY	$0.59 - $0.87 $81,356 - $119,966	137,893 Added 28.91%	614,938 $405,000
Q1 2023 May 15, 2023	BUY	$0.65 - $2.3 $58,796 - $208,048	90,456 Added 23.4%	477,045 $380,000
Q4 2022 Feb 14, 2023	BUY	$1.39 - $2.98 $294,973 - $632,388	212,211 Added 121.7%	386,589 $874,000
Q3 2022 Nov 14, 2022	SELL	$1.76 - $4.94 $73,550 - $206,442	-41,790 Reduced 19.33%	174,378 $337,000
Q2 2022 Aug 15, 2022	BUY	$2.47 - $6.77 $533,934 - $1.46 Million	216,168 New	216,168 $804,000
Q1 2022 May 16, 2022	SELL	$5.22 - $11.86 $313,455 - $712,181	-60,049 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$11.43 - $19.2 $686,360 - $1.15 Million	60,049 New	60,049 $700,000
Q3 2021 Nov 15, 2021	SELL	$15.82 - $21.57 $477,210 - $650,659	-30,165 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$19.29 - $26.38 $174,381 - $238,475	9,040 Added 42.79%	30,165 $639,000
Q1 2021 May 17, 2021	BUY	$20.3 - $31.75 $35,017 - $54,768	1,725 Added 8.89%	21,125 $429,000
Q4 2020 Feb 16, 2021	SELL	$19.14 - $28.13 $2.94 Million - $4.33 Million	-153,857 Reduced 88.8%	19,400 $515,000
Q3 2020 Nov 16, 2020	BUY	$22.4 - $24.47 $3.88 Million - $4.24 Million	173,257 New	173,257 $3.88 Million

119

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $103M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.